PRostAte Cancer vTe In SwEden: epidemiology and anticoagulation treatment of VTE (PRACTISE)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/44410
• EU PAS number:
  EUPAS29848
• Study ID:
  44410
• Official title and acronym:
  PRostAte Cancer vTe In SwEden: epidemiology and anticoagulation treatment of VTE (PRACTISE)
• DARWIN EU® study:
  No
• Study countries:
  Sweden
• Study status:
  Finalised

Research institution and networks

Institutions

Bayer AG

Study timelines

Date when funding contract was signed

Actual: 12/05/2019

Study start date

Planned: 30/05/2019

Actual: 30/05/2019

Date of final study report

Planned: 23/09/2021

Actual: 23/08/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer AG

Study protocol

Initial protocol

20653_Study Protocol_V1.0_2019-05-12_redacted

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable